Myomo, Inc. Announces Closing of Public Offering and Full Exercise of Over-Allotment Option

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable
medical robotics company that offers increased functionality for those
suffering from neurological disorders and upper limb paralysis, today
has closed its previously announced underwritten public offering of
3,950,000 shares of common stock at an offering price of $1.40 per
share. In connection with the offering, the underwriter exercised in
full its over-allotment option to purchase an additional 592,500 shares
of common stock at the public offering price, less underwriting
discounts and commissions. All of the shares of common stock were
offered by the Company.

In total, the public offering size was 4,542,500 shares of common stock
and the gross proceeds were approximately $6.4 million, before deducting
underwriting discounts and other offering expenses.

Myomo intends to use the net proceeds from the offering for working
capital and other general corporate purposes. National Securities
Corporation, a wholly owned subsidiary of National Holdings Corporation
(NASDAQ: NHLD), acted as sole book-running manager for the proposed

A shelf registration statement on Form S-3 relating to the shares of
common stock being offered was filed with the Securities and Exchange
Commission (the “SEC”) and is effective. Copies of the final prospectus
supplement and the accompanying base prospectus relating to this
offering may be obtained from: National Securities Corporation,
Attention: Christopher Passarelli, 200 Vesey Street, 25th Floor, New
York, New York 10281, telephone: (212) 417-8164 or by email at;
or on the SEC’s website at

This announcement shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there be any
offer or sale of these securities in any state or jurisdiction in which
such an offer, solicitation or sale would be unlawful.

About Myomo

Myomo, Inc. is a wearable medical robotics company that offers expanded
mobility for those suffering from neurological disorders and upper limb
paralysis. Myomo develops and markets the MyoPro product line. MyoPro is
a powered upper limb orthosis designed to support the arm and restore
function to the weakened or paralyzed arms of patients suffering from
CVA stroke, brachial plexus injury, traumatic brain or spinal cord
injury, ALS or other neuromuscular disease or injury. It is currently
the only marketed device that, sensing a patient’s own EMG signals
through non-invasive sensors on the arm, can restore an individual’s
ability to perform activities of daily living, including feeding
themselves, carrying objects and doing household tasks. Many are able to
return to work, live independently and reduce their cost of care. Myomo
is headquartered in Cambridge, Massachusetts, with sales and clinical
professionals across the U.S. For more information, please visit

Safe Harbor

All statements in this release that are not based on historical fact are
“forward-looking statements.” While management has based any
forward-looking statements included in this release on its current
expectations, the information on which such expectations were based may
change. Forward-looking statements involve inherent risks and
uncertainties which could cause actual results to differ materially from
those in the forward-looking statements, as a result of various factors
including those risks and uncertainties described in the prospectus
supplement and accompanying prospectus, including our other filings with
the SEC that are incorporated by reference therein, which can be found
on the SEC’s website at
We urge you to consider those risks and uncertainties in evaluating our
forward-looking statements. We caution readers not to place undue
reliance upon any such forward-looking statements, which speak only as
of the date made. Except as otherwise required by the federal securities
laws, we disclaim any obligation or undertaking to publicly release any
updates or revisions to any forward-looking statement contained herein
(or elsewhere) to reflect any change in our expectations with regard
thereto or any change in events, conditions or circumstances on which
any such statement is based.


Investor Relations:
Vivian Cervantes
PCG Advisory


Matter Communications
Sarah Karr

error: Content is protected !!